CN1889952A - (a)N－{5－[4－(4－甲基－(哌嗪－1－基)－甲基)－苯甲酰胺基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺和( b )至少一种羟丁赖氨酸形成抑制剂的组合产品及其用途 - Google Patents

(a)N－{5－[4－(4－甲基－(哌嗪－1－基)－甲基)－苯甲酰胺基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺和( b )至少一种羟丁赖氨酸形成抑制剂的组合产品及其用途 Download PDF

Info

Publication number
CN1889952A
CN1889952A CNA2004800362740A CN200480036274A CN1889952A CN 1889952 A CN1889952 A CN 1889952A CN A2004800362740 A CNA2004800362740 A CN A2004800362740A CN 200480036274 A CN200480036274 A CN 200480036274A CN 1889952 A CN1889952 A CN 1889952A
Authority
CN
China
Prior art keywords
combination
leukemia
methyl
imatinib
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800362740A
Other languages
English (en)
Chinese (zh)
Inventor
T·H·布吕门多夫
S·巴拉巴诺夫
U·哈特曼
W·卡默
A·努尔海姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1889952A publication Critical patent/CN1889952A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800362740A 2003-12-19 2004-12-17 (a)N－{5－[4－(4－甲基－(哌嗪－1－基)－甲基)－苯甲酰胺基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺和( b )至少一种羟丁赖氨酸形成抑制剂的组合产品及其用途 Pending CN1889952A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19
US60/531,563 2003-12-19

Publications (1)

Publication Number Publication Date
CN1889952A true CN1889952A (zh) 2007-01-03

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800362740A Pending CN1889952A (zh) 2003-12-19 2004-12-17 (a)N－{5－[4－(4－甲基－(哌嗪－1－基)－甲基)－苯甲酰胺基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺和( b )至少一种羟丁赖氨酸形成抑制剂的组合产品及其用途

Country Status (17)

Country Link
US (1) US20080139480A1 (https=)
EP (1) EP1696917A1 (https=)
JP (1) JP2007514699A (https=)
KR (1) KR20060125810A (https=)
CN (1) CN1889952A (https=)
AU (2) AU2004298761A1 (https=)
BR (1) BRPI0417759A (https=)
CA (1) CA2547196A1 (https=)
EC (1) ECSP066656A (https=)
IL (1) IL176070A0 (https=)
MA (1) MA28240A1 (https=)
MX (1) MXPA06006925A (https=)
NO (1) NO20063326L (https=)
RU (1) RU2006125741A (https=)
TN (1) TNSN06182A1 (https=)
WO (1) WO2005058320A1 (https=)
ZA (1) ZA200603904B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用
CN104945318A (zh) * 2010-06-01 2015-09-30 拜欧赛里克斯公司 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197440B1 (en) 2007-08-31 2012-12-26 Janssen Pharmaceutica, N.V. Combinations of imazalil and hydroxypyridones
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
US8575187B2 (en) 2008-02-06 2013-11-05 Janssen Pharmaceutica, Nv Combinations of anilinopyrimidines and pyrion compounds
CA2711762C (en) 2008-02-06 2016-11-01 Jan Pieter Hendrik Bosselaers Combinations of phenylpyrroles and pyrion compounds
WO2010048712A1 (en) * 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
JP6019015B2 (ja) * 2010-06-01 2016-11-02 ビオトヘルイク， インコーポレイテッド ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法
CN102917591B (zh) 2010-06-10 2014-07-23 詹森药业有限公司 嘧霉胺和单萜烯的组合
EP2587920B1 (en) 2010-07-01 2016-08-10 Janssen Pharmaceutica, N.V. Antimicrobial combinations of pyrion compounds with polyethyleneimines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (en) * 1985-11-25 1987-07-01 The Hospital For Sick Children Use of chelating agents
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
ES2331562T3 (es) * 2001-03-23 2010-01-08 Enzon, Inc. Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos.
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945318A (zh) * 2010-06-01 2015-09-30 拜欧赛里克斯公司 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Also Published As

Publication number Publication date
MA28240A1 (fr) 2006-10-02
NO20063326L (no) 2006-09-19
RU2006125741A (ru) 2008-01-27
EP1696917A1 (en) 2006-09-06
ECSP066656A (es) 2006-10-25
KR20060125810A (ko) 2006-12-06
US20080139480A1 (en) 2008-06-12
BRPI0417759A (pt) 2007-04-10
TNSN06182A1 (en) 2007-11-15
AU2009201694A1 (en) 2009-05-28
AU2004298761A1 (en) 2005-06-30
JP2007514699A (ja) 2007-06-07
IL176070A0 (en) 2006-10-05
MXPA06006925A (es) 2006-08-23
CA2547196A1 (en) 2005-06-30
ZA200603904B (en) 2007-09-26
WO2005058320A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
US12370195B2 (en) Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
US11938124B2 (en) Combination therapy for treatment of cancer
US11136297B2 (en) Compositions and methods for treating cancer
US20240261284A1 (en) Intermittent dosing of mdm2 inhibitor
AU2009201694A1 (en) Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
JP2020521741A (ja) がんの処置のための化合物およびその使用の方法
CN113490512A (zh) 组合药剂
US20240245634A1 (en) Pcna inhibitors and egfr inhibitors for cancer treatment
US20190117663A1 (en) Compositions and methods for treating cancer
US10744133B2 (en) Compound for anti-cancer therapy that acts by targeting GOF mutant p53 and stimulates p73 to restore the p53 pathway signaling
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
EP1667719B1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
JP2009504674A (ja) 有機化合物の組合せ
EP2237783B1 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib
JP2005527552A (ja) 置換アクリロイルジスタマイシン誘導体および放射線療法を含む腫瘍に対する組合せ治療
AU2013201993B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
HK40057625A (en) Combinational medication
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor
HK1151238A (en) Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070103